Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 2, 2026, 8:05 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1537–1560 of 3,499 matching trials from the live ClinicalTrials.gov search.
Conditions
Chronic Renal Failure, Chronic Kidney Disease, Anemia
Interventions
peginesatide, Darbepoetin alfa
Drug
Lead sponsor
Affymax
Industry
Eligibility
18 Years and older
Enrollment
490 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
68
States / cities
Montgomery, Alabama • Tempe, Arizona • Hot Springs, Arkansas + 62 more
Completed Phase 4 Interventional Results available

Linagliptin Inpatient Trial

NCT02004366
Conditions
Type 2 Diabetes
Interventions
Linagliptin, Basal Bolus, Linagliptin + 50% Glargine dose on discharge, Linagliptin + 80% Glargine
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
295 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
5
States / cities
Denver, Colorado • Atlanta, Georgia • Chicago, Illinois + 1 more
Conditions
Traumatic Brain Injury
Interventions
Genotropin
Drug
Lead sponsor
Joe Springer
Other
Eligibility
18 Years to 55 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Lexington, Kentucky
Conditions
Prostate Cancer
Interventions
exercise intervention, nutritional supplementation, quality-of-life assessment, questionnaire administration, pharmacological study, laboratory biomarker analysis
Behavioral · Dietary Supplement · Procedure + 1 more
Lead sponsor
University of Southern California
Other
Eligibility
50 Years and older · Male only
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Orthostatic Hypotension, Parkinson's Disease
Interventions
Droxidopa, Placebo
Drug · Other
Lead sponsor
Chelsea Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
60
States / cities
Alabaster, Alabama • Gilbert, Arizona • Phoenix, Arizona + 53 more
Conditions
Diffuse Cutaneous Systemic Sclerosis
Interventions
IgPro10, Placebo
Biological
Lead sponsor
CSL Behring
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
20
States / cities
Scottsdale, Arizona • Los Angeles, California • Palo Alto, California + 15 more
Conditions
Craniosynostosis
Interventions
Amicar (ε-aminocaproic acid), normal saline
Drug
Lead sponsor
Children's National Research Institute
Other
Eligibility
2 Months to 36 Months
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2028
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
Diabetes Mellitus, With Complications
Interventions
Effect of Pulsatile IV Insulin on diabetic neuropathy
Procedure
Lead sponsor
Florida Atlantic University
Other
Eligibility
20 Years to 90 Years
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Boca Raton, Florida
Completed No phase listed Observational Accepts healthy volunteers

Neuroimaging of Dystonia

NCT02046447
Conditions
Primary Cervical Dystonia, DYT 1 Dystonia
Interventions
Primary Cervical Dystonia (Trihexyphenidyl), Controls Primary Cervical Dystonia (Trihexyphenidyl), DYT 1 Dystonia (Healthy Control), DYT 1 Dystonia
Drug · Other
Lead sponsor
University of Florida
Other
Eligibility
7 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Gainesville, Florida
Conditions
Pain, Postoperative, Scoliosis Idiopathic
Interventions
Gabapentin, Placebo
Drug · Other
Lead sponsor
Emory University
Other
Eligibility
10 Years to 18 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Acute-graft-versus-host Disease
Interventions
AAT, Placebo
Biological
Lead sponsor
CSL Behring
Industry
Eligibility
12 Years and older
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
12
States / cities
Scottsdale, Arizona • St. Petersburg, Florida • Atlanta, Georgia + 9 more
Conditions
Non-small Cell Lung Cancer
Interventions
Tobemstomig, Pembrolizumab, Paclitaxel, Pemetrexed, Carboplatin
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
2
States / cities
Detroit, Michigan • Reno, Nevada
Conditions
Tyrosol, Creatine, Endurance Performance, Cognition, Mood
Interventions
Tyrosol, Creatine Monohydrate, Resistant Dextrin
Dietary Supplement
Lead sponsor
Applied Science & Performance Institute
Industry
Eligibility
20 Years to 55 Years · Male only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Tampa, Florida
Completed Not applicable Interventional Accepts healthy volunteers

Breakfast Consumption and Energy Balance in Active Adult Males

NCT04862208
Conditions
Energy Intake, Substrate Utilization, Hormones, Satiety
Interventions
Maltodextrin supplement, Whey supplement, Water
Dietary Supplement
Lead sponsor
Ohio University
Other
Eligibility
18 Years to 45 Years · Male only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Athens, Ohio
Conditions
Immediate Post-Treatment Care, Aging Mid-Face, Aging
Interventions
ariessence pure PDGF+™ is a sterile aqueous formulation containing Hyaluronic Acid and pure platelet-derived growth factor (PDGF).
Other
Lead sponsor
Lynch Regenerative Medicine
Network
Eligibility
40 Years to 70 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Sacramento, California • Nashville, Tennessee
Conditions
Anaemia
Interventions
Daprodustat, Darbepoetin alfa, Placebo, Iron Therapy
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 99 Years
Enrollment
3,872 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
161
States / cities
Andalusia, Alabama • Birmingham, Alabama • Huntsville, Alabama + 128 more
Conditions
Acute Pain
Interventions
Gabapentin
Drug
Lead sponsor
Denver Health and Hospital Authority
Other
Eligibility
18 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Denver, Colorado
Conditions
Metastatic Pancreatic Ductal Adenocarcinoma
Interventions
ONT01, Gemcitabine, Nab paclitaxel
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
St Louis, Missouri
Completed Early Phase 1 Interventional Accepts healthy volunteers

Menthol Stimulation of Brown Adipose Tissue in Humans: Aim 1

NCT07030725
Conditions
Regulation of Energy Expenditure
Interventions
Menthol Gel, Sham, Time control
Drug · Behavioral
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 40 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Bloomington, Indiana
Conditions
Overweight and Obesity
Interventions
Financial incentives
Other
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Omaha, Nebraska
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Immunogenicity of IVX-A12 in Healthy Older Adults

NCT05664334
Conditions
Healthy
Interventions
IVX-121, IVX-241, Placebo, MF59®
Biological · Other
Lead sponsor
Icosavax, Inc.
Industry
Eligibility
60 Years to 75 Years
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
4
States / cities
Hollywood, Florida • Atlanta, Georgia • Omaha, Nebraska + 1 more
Conditions
Dry Eye, Meibomian Gland Dysfunction
Interventions
TearCare System, Cyclosporine Ophthalmic 0.05% Ophthalmic Emulsion
Device · Drug
Lead sponsor
Sight Sciences, Inc.
Industry
Eligibility
22 Years and older
Enrollment
345 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
14
States / cities
Scottsdale, Arizona • La Jolla, California • Laguna Hills, California + 11 more
Terminated Phase 3 Interventional Results available

Hypertension in Hemodialysis Patients (Aim 3)

NCT00582114
Conditions
Hemodialysis, Hypertension, Left Ventricular Hypertrophy
Interventions
Lisinopril, Atenolol
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
1
States / cities
Indianapolis, Indiana
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

Treatment of Facial Flushing With Botulinum Toxin A Injections

NCT02216838
Conditions
Facial Flushing
Interventions
botulinum toxin A, Saline Control
Drug · Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2027
U.S. locations
1
States / cities
Chicago, Illinois